Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression

Fu-Ju Chou a,1, Yuhchyau Chen 2,1, Dong Chen c, Yuanjie Niu a, Gonghui Li a, Peter Keng a, Shuyuan Yeh a, Chawnshang Chang a,b,*

a George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
b Sex Hormone Research Center, China Medical University and Hospital, Taichung 404, Taiwan
c Department of Urology, National Cancer Center/Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

Article history:
Received 7 July 2018
Received in revised form 20 December 2018
Accepted 20 December 2018
Available online 26 January 2019

ABSTRACT

Background: While androgen deprivation therapy (ADT) and radiotherapy (RT) are currently used together to treat locally advanced prostate cancer (PCa), RT might have the adverse effect of increasing the PCa androgen receptor (AR) protein expression, which might then increase the resistance to continued RT.

Methods: We used multiple assays for RT sensitivity, protein and RNA expression of AR and related DDR genes, ROS level, DNA damage/repair level, cell cycle and apoptosis. All statistical comparisons were analyzed with t-test or one-way ANOVA.

Findings: We demonstrated that RT induced AR expression in C4-2 and CWR22Rv-1 cells. We found that combining RT and ASC-J9®, but not the antiandrogen, Enzalutamide, could increase radiosensitivity via inducing DNA damage, altering the AR mediated and DNA repair pathways, and activating apoptosis. ASC-J9® had little effects on normal bladder cells.

Interpretation: Targeting ionizing radiation (IR)-increased AR with the AR degradation enhancer, ASC-J9®, could increase the radiosensitivity while sparing adjacent normal tissue. Mechanism dissection revealed that ASC-J9®, but not Enzalutamide, treatment could increase radiosensitivity via inducing DNA damage, altering DNA repair pathways, as well as activating the IR-induced apoptosis via suppressing the pATR-CHK1 signals. Importantly, results from preclinical studies using an in vivo mouse model also demonstrated that combining RT with ASC-J9® to target AR led to better therapeutic efficacy to suppress PCa progression.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Prostate cancer (PCa), a common cancer among men worldwide, has been increasing in the recent years with 1 out of 6 men being diagnosed during their lifetime [1]. Radiation therapy (RT) is a popular treatment choice among patients with localized or locally advanced PCa that is categorized as either low risk PCa (≤ T2a, PSA ≤ 10 ng/dL, and Gleason score < 7), intermediate risk PCa (PSA > 10–20, Gleason score = 7, or clinical stage T2b or T2c) or high-risk PCa (PSA > 20, Gleason score between 8 and 10 or clinical stage T3a). However, nearly 25% of intermediate and high-risk PCa tumors recur after RT.

Importantly, RT can be combined with a course of androgen deprivation therapy (ADT) using various antiandrogens together with RT [2,3]. The result has a proven overall survival advantage, thereby establishing it as standard-of-care for high-risk localized PCa. While ADT + RT provides therapeutic benefit for PCa patients, yet it may also be accompanied with some adverse effects, including depression, hot flashes, fatigue, and loss of bone/muscle mass, which seriously compromise the quality-of-life of patients. Several therapeutic approaches, including β-lapachone [4] or resveratrol (RSV) [5], were developed to enhance the RT efficacy to further suppress PCa progression with fewer adverse effects of urinary and/or erectile dysfunction.

Recent studies indicated that androgen effects might not be equal to the androgen receptor (AR) effects and ADT with antiandrogens [6] may only reduce the androgen biosynthesis or prevent androgen from binding to AR, with little effect on the AR expression [7–11]. Since more and more data indicated that AR, at the castration concentration (1–2 nM) of androgens, could also be transactivated by various growth...
AR mediates 144 DDR genes and directly targets 32 of them, which may result in radiation resistance. ADT plus RT are currently used together to treat localized and locally advanced prostate cancer (PCa), and improve cause-specific survival. Clinically, nearly 20% of RT patients have rising serum levels of AR-regulated hK2 protein, which provides evidence of AR pathway upregulation after RT.

**2. Materials and methods**

**2.1. Cell lines and cell cultures**

We used two different PCa cell lines (C4-2 and CWR22Rv-1; ATCC Cat# CRL-3315, RRID:CVCL_4782 and Cat# CRL-2505, RRID: CVCL_1045), one normal bladder epithelial cell line (SV-HUC; ATCC Cat# CRL-9520, RRID:CVCL_3798), and the 293T cell line. C4-2 and CWR22Rv-1 cells were maintained in RPMI 1640, SV-HUC cells in F-12K media, and 293T cells in DMEM media, all with penicillin (25 units/ml), streptomycin (25 g/ml), 1% L-glutamine, and 10% fetal bovine serum (FBS). For thecaization resistant condition, the 10% FBS medium was replaced with phenol red free media containing 10% charcoal-depleted (CD) FBS and 1 nM DHT (this concentration simulates ADT, because it replicates the DHT concentration remaining in the tumors of PCa patients following castration).

2.2. Plasmids and lentivirus

A recombinant lentiviral vector containing AR-shRNA (pLKO-shAR) and a scramble lentiviral control vector (pLKO-Scr) were used to knock-down AR. To generate the recombinant lentivirus, lentiviral pLKO-shAR/pLKO-Scr with pMD2.G packaging and psPAX2 envelope plasmids (lentivirus:packaging:envelope, 2:1:1) were co-transfected into 293 T cells for 6 h, and then were changed to normal media for immediate use or frozen at −80 °C for later use. For the virus infection, viral supernatants were added to the target cells with 8 mg/ml polybrene (Millipore, Billerica, MA, USA) to prepare stable cell line clones.

2.3. Chemical compounds

ASC-J9® (PubChem CID: 6477182) was purchased from AndroScience Corp. (San Diego, CA, USA). Enzalutamide (PubChem CID: 15951529) was purchased from MedChem Express (Monmouth Junction, New Jersey, USA). Casodex (PubChem CID: 23735) was purchased from Toronto Research Chemicals (North York, ON, CAN). Drug stocks (10 mM) were dissolved in DMSO and stored at −20 °C.

2.4. Clonogenic survival assays

Cells were plated in 60-mm culture dishes at various densities of cells per plate, depending on the IR dosage used, and allowed to attach overnight. Media were changed to castration resistant condition (10% CD-FBS + 1 nM DHT) for 24 h. For assay of the long-term survival rate (Clonogenic forming assay), cells were treated with 1 μM or 2·5 μM ASC-J9® for 6 h, and then cells were irradiated (Cs137 radiator, URMC, Rochester, NY, USA). The drugs were removed as soon as possible after irradiation (the irradiation source is in a different area of the Medical Center away from the lab) and cells incubated for 14 days. The colonies were fixed with 10% methanol and stained with 1% Toluidine blue. Colonies containing >50 cells were counted using a stereomicroscope. The mean normalized surviving fraction from three similar independent experiments was calculated and the SEM reported.

2.5. TUNEL assay

Cells were plated on coverslips and allowed to attach overnight. Media was changed to castration resistant condition (10% CD-FBS + 1 nM DHT) for 24 h, cells were treated with 1 μM or 2·5 μM ASC-J9® for 6 h, and then cells were irradiated (Cs137 radiator). The drugs were removed as soon as possible after irradiation. Samples were harvested 24 h after irradiation, fixed with 4% paraformaldehyde, incubated with 0.5% Triton X-100 in PBS, and blocked with 3% H2O2 in methanol. Then cells were stained with Cell Death Detection Kit (Roche, No. 11684817910). Apoptotic cells were visualized by fluorescence microscope at 20× power magnification. The total number of cells (DAPI was used for counter-staining) and apoptotic cells were counted in 3 random fields to calculate the apoptosis percentage.

2.6. Alkaline comet assay

C4-2, CWR22Rv-1, and SV-HUC cells were grown, treated, and irradiated under the described conditions. DNA lesions, including total base damage, double strand breaks (DSBs) and single strand breaks (SSBs), were assessed using single-cell gel electrophoretic comet assays under alkaline conditions (TREVIGEN, Gaitherburg, MD, USA), according to the manufacturer’s instructions. Slides were stained with SYBR Gold (S11494, Thermo Fisher Scientific, Waltham, MA, USA) and visualized using a fluorescence microscope. Digital photomicrographs were taken and comet tail lengths quantified using alpha-image 2000. Each datum point represents an average of 5 cells ± SEM, and data are representative of experiments performed in triplicate.
2.7. Analysis of ROS Levels

C4-2 cells were plated at 4 \times 10^6 cells/well, allowed to attach overnight, and treated with a series of doses of ASC-J9\(^{\text{®}}\) (1, 2, 5, or 5 \mu M) or DMSO for 16 h. The cells were then washed with a PBS solution containing 0.14 g of CaCl\(_2\) and 0.1 g of MgCl\(_2\) in 11 of DPBS. The cells were then incubated with 10 \mu M 2′,7′-dichlorofluorescein diacetate (DCF-DA) (#ab113851, Abcam, Cambridge, UK) for 1 h at 37 °C before irradiation. Test plates were irradiated at 10 Gy (control plates were taken to the source for the same time frame away from the lab as with test plates), and the fluorescence was measured for all the plates using an ELISA reader at an absorption wavelength of 485 nm and emission wavelength of 520 nm. The results were expressed as relative fluorescence, normalized to un-irradiated control.

2.8. Glutathione detection

Endogenous levels were measured according to instructions from the GSH-Glo\textsuperscript{TM} Glutathione Assay Kit (#V6911, Promega, Madison, WI, USA). Briefly, PCa cells were grown under described conditions in 96-well plates, with approximately 5000 cells/well in 200 \mu l total volume. After 16 h ASC-J9\(^{\text{®}}\) treatment, we carefully removed the culture media from the wells, added 100 \mu l of prepared 1× GSH-Glo\textsuperscript{TM} Reagent to each well, and incubated at room temperature for 30 min. After incubation, 100 \mu l of reconstituted Luciferin Detection Reagent was added and luminescence measured by ELISA reader.

2.9. γ-H2AX assay

PCa cells were grown under described conditions for 2 days on coverslips, with approximately 2000 cells/well in 1 ml total volume. Following IR, coverslips were washed and cells fixed with 4% paraformaldehyde and 0.2% Triton X-100, blocked with 2% Bovine Serum Albumin (#A2058, Sigma-Aldrich,) and 0.5% Triton X-100, and then were incubated with γ-H2AX (Millipore Cat# 05–636, RRID:AB_309864) overnight at 4 °C. Coverslips were then washed, incubated with secondary antibody (Goat anti-Mouse IgG Alexa Fluor 488 Dye; #: R37120 Thermofisher Scientific, St. Louis, MO, USA) for 1 h at room temperature, and stained with 4′,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI; #D1306 Thermofisher Scientific). Foci (green signal) number of each nuclei were compared under 60× power fields under a fluorescent microscope.

2.10. Quantitative real-time PCR

Total RNA was isolated using the TRIzol\textsuperscript{®} Reagent (#15596026 Thermofisher Scientific) according to the manufacturer’s instructions. Total RNA was reverse transcribed into cDNA using iScript\textsuperscript{TM} cDNA Synthesis Kit (# 1708891, BioRad, Hercules, CA, USA). The primer sequences were listed in the Table S1. The qRT-PCR was performed using the Bio-Rad iQ5 real-time thermal cycler and iQ\textsuperscript{™} SYBR\textsuperscript{®} Green Supermix (#1708880, Biorad). Relative mRNA expression levels were normalized against GAPDH (as an internal control) and determined by the 2 − ΔΔCt method. QPCR primer list is in Supplementary Table S1.

2.11. Homologous recombination DR-GFP assay

2 \times 10^6 293 T cells in 6-well plates were transfected with 0.7 \mu g of pDR-GFP plasmid (#26475, Addgene, Watertown, MA, USA) and 2 \mu g of I-Sce1 expression plasmid pCBAscel (#26477, Addgene) using lipofectamine\textsuperscript{TM} 2000 (#11668019, Thermofisher Scientific). After 48 h, GFP positive and total cells were counted in 5 random high-power fields under a fluorescent microscope.

2.12. Protein analysis

For western blot analyses, protein extracts of each sample (50 \mu g/lane) were electrophoretically separated and transferred onto PVDF membranes that were incubated with antibodies against AR (Santa Cruz Biotechnology Cat# sc-816, RRID:AB_1563391), pATR (GeneTex Cat# GTX128145, RRID:AB_2687562), cleaved PARP, pCHK1 (Cell Signaling Technology Cat# 9546, RRID:AB_2160593, and Cat# 2348, RRID:AB_331212), and GAPDH (Santa Cruz Biotechnology Cat# sc-48166, RRID:AB_783595), followed by horseradish peroxidase-conjugated secondary antibody. Protein-antibody complexes were detected by SuperSignal\textsuperscript{TM} West Femto Maximum Sensitivity Substrate (#34095, ThermoFisher Scientific) using the Bio-Rad imaging system.

2.13. Formation of xenograft and γ-radiation

C4-2 cells (5 \times 10^5) were injected s.c. into the right flank of 6–8 week-old nude mice (National Cancer Institute, Rockville, MD, USA). Mice were castrated 14 days after tumor cell inoculation. Xenografts reaching >100 mm\(^3\) were i.p. injected with vehicle or 75 mg/kg ASC-J9\(^{\text{®}}\) every other day, for a total of 3 times. Mice were exposed to 8Gy γ-ray (IR) at 16 h after the second ASC-J9\(^{\text{®}}\) treatment, but the mock control or ASC-J9\(^{\text{®}}\) only group were not irradiated. Mice were anesthetized i.p. with Avertin (2,2,2-tribromoethanol, # T48402-25G, Sigma-Aldrich) (when irradiated) or isoflurane (to measure tumor sizes) (NDC 11695-0500-2, Henry Schein, Melville, NY, USA). Xenografts were locally irradiated with a Model 8114 600 Ci Shepherd Cs\(^{137}\) irradiator (URMC), while other body parts were protected with lead shielding. Tumor regrowth curves of the mice were assessed for an additional 24 days. Tumor sizes were established with calipers (VWR, Radnor, PA, USA), and the volume of each xenograft calculated as follows: \((\text{short axis}^2 \times \text{long axis})/2\). Ethics statement: The PCa xenograft mice study protocol was approved by the University Committee on Animal Resources (UCAR) and monitored by the Radiation Safety Unit. All the nude mice were ordered from NCI and were maintained in URMC vivarium facilities which is accredited by Accreditation of Laboratory Animal Care International (AAALAC).

2.14. Statistics

The data values were presented as the mean ± SEM. Differences in mean values between two groups were analyzed by two-tailed Student’s t-test. The p ≤ 0.05 was considered statistically significant. Error bars represent SEM from three independent fields under microscopy and/or from at least 3 independent experiments. Limitation: multiple comparisons are made without adjustment for multiple-hypothesis testing (e.g. Bonferroni’s correction).

3. Results

3.1. Radiation increased AR expression in castration resistant prostate cancer cells

According to NCCN Guidelines, RT combined with ADT with antiandrogens to either reduce androgen synthesis or prevent androgens from binding to AR are used currently as the standard therapy to treat advanced PCas [22]. While several studies indicated that ADT might have some adverse effects [23], the impact of RT on the AR expression remains unclear.

To study the potential RT effects on the AR expression, we first exposed the castration resistant prostate cancer (CRPC) C4-2 and CWR22Rv-1 cells to 4Gy IR under the castration conditions (1 nM DHT), and results revealed that radiation could increase AR expression at both mRNA and protein levels (Fig. 1a-b, respectively).
which might then increase the AR transactivation (Fig. 1c) and AR downstream targets related to the DNA damage response (DDR) signals (Fig. 1d).

This unexpected finding showing radiation may increase AR protein may have significant clinical implications, since elevated AR may counteract effects of ADT with antiandrogens. Elevated AR indeed has many
adverse effects on the continuation of RT or subsequent ADT treatment to suppress PCa progression.

We also confirmed our finding via targeting the radiation-increased AR with either the AR degradation enhancer ASC-J9® or AR-shRNA, or FDA-approved antiandrogen Enzalutamide (Enz, also named MDV3100). As expected, we found combining IR with ASC-J9® treatment suppressed the IR-induced AR protein expression, yet IR combined with Enz failed to suppress the IR-induced AR protein expression (Fig. 1a).

3.2. ASC-J9® increased radiosensitivity in CRPC cells with little injury to normal bladder cells

To examine the potential impacts for ASC-J9® on the radiosensitivity, we applied the clonogenic forming assay to measure radiosensitivity on CRPC vs bladder epithelial SV-HUC cells to evaluate the possible side effects in bladder tissue, which is adjacent to prostate during RT. We treated CRPC C4-2 cells with a sub-lethal dose of ASC-J9® (1.0 μM or 2.5 μM, see the sub-lethal dose condition test in Supplementary Fig. S1a-c) for 6 h and then irradiated with various doses (from 1 Gy–7 Gy) of IR, and results revealed that treating with 2.5 μM ASC-J9® followed by IR significantly reduced clonogenic survival, compared to the radiation alone or ASC-J9® treatment alone (Fig. 2a). Similar, but not as dramatic, results were observed when we replaced C4-2 with CWR22Rv-1 cells (Fig. 2b).

We want to know whether combining IR with ASC-J9® damaged normal bladder cells, may result in a potential adverse effect on the urinary bladder (radiation cystitis), since it is critical for radiosensitizers to selectively target tumor cells with little damage to the neighboring normal cells. We applied the in vitro assay of normal bladder cells to test this concept. The results revealed that ASC-J9® treatment resulted in little damage on the normal bladder SV-HUC cells (Fig. 2c). These results match well the early studies showing ASC-J9® could degrade AR with fewer adverse effects in various mouse models.

Similar results were also obtained when we replaced ASC-J9® with AR-shRNA to decrease AR expression in C4-2 cells (Fig. 2d), suggesting that targeting AR protein contributes to increased radiation sensitivity to better suppress PCa.

In contrast, we found treatment with Enz failed to decrease AR protein expression and could not provide the similar benefit to increase radiation sensitivity as 2.5 μM ASC-J9® (Fig. 2e).

Together, results from Fig. 2a–e and Supplementary Fig. S1 suggest that treating cells with ASC-J9® to decrease the IR-increased AR protein expression can increase radiosensitivity to better suppress PCa without damaging normal bladder cells.

3.3. Mechanism dissection of why ASC-J9®-decreased AR expression can increase RT sensitivity: inducing apoptosis via altering the AR dependent ATR-CHK1 pathway

To dissect the mechanisms of why ASC-J9®-decreased AR expression increases RT sensitivity, we focused on the following 3 different mechanisms: apoptosis, suppressing the DNA damage response (DDR) system, and inducing the DNA damage pathways [24].

We first examined the impact of ASC-J9® on IR-induced apoptosis in PCa cells, since early studies indicated that PCa was highly resistant to γ-H2AX, an in situ marker, to check un-repaired DNA breaks since early studies indicated visualization of γ-H2AX allowed the assessment of DNA repair [31].

Our results in C4-2 and CWR22Rv-1 cells revealed that persistent γ-H2AX foci numbers (Fig. 4a–b) and amounts (Fig. 4c–d) increased after IR in an ASC-J9® dose-dependent manner after 6 h treatment with ASC-J9®, suggesting that ASC-J9® has the capacity of increasing radiosensitivity through suppressing the DNA repair response. As expected in both cell lines, treating with CAD or Enz failed to suppress γ-H2AX amount (Fig. 4e–f) since these anti-androgens failed to decrease AR protein expression, and therefore also failed to trigger the radiation-induced DNA repair process to alter the DDR activation.

The results from Fig. 4a–h and Supplementary Table S2–S3 suggest that ASC-J9® may also function through suppressing the radiation-induced DNA repair process to alter the radiosensitivity.
3.5. Mechanism dissection of why ASC-J9®-decreased AR expression can increase RT sensitivity: inducing DNA damage by ROS generation and altering GSH level

The 3rd mechanism of how ASC-J9®-decreased AR expression can increase radio sensitivity may involve altering the peroxidative damage with modulating the intra-cellular reactive oxygen species (ROS) to enhance the DNA damage [33]. We first applied the alkaline comet assay [34] to evaluate the overall level of DNA breaks (including SSB and DSB) after ASC-J9® treatment + IR. PCa cells were treated with ASC-J9® for 6 h and then exposed to 4 Gy IR. The results in Fig. 5a–b revealed that ASC-J9® with IR dramatically enhanced IR-induced DNA damage (increased tail/body ratio) as compared to control groups in both the C4-2 (Fig. 5a) and CWR22Rv-1 (Fig. 5b) cells.

Fig. 2. Differential radiosensitization effects of ASC-J9® in prostate cancer cells vs. normal bladder cells. (a-b) Clonogenic survival was reduced with the combined treatment of ASC-J9® (J9) + IR in C4-2 (a) and CWR22Rv1 (b) cells. (c) ASC-J9® + IR together results in only very minor effects in SV-HUC cells. (d) AR-shRNA + IR decreased clonogenic survival rate compared to scr control + IR. (e) Treatments with current antiandrogens could not enhance radio-sensitivity in C4-2 cells compared to ASC-J9® treatment. Three independent experiments were performed in triplicate and mean ± SEM has been plotted. Representative images are shown in bottom panels of each section. "P < 0.05, "*P < 0.01, "**P < 0.001.

**F.-J. Chou et al. / EBioMedicine 40 (2019) 504–516**
Fig. 3. The TUNEL positive cells are increased and apoptosis is promoted via atypical PARP after combination treatment of ASC-J9® and IR in PCa cells. (a-b) TUNEL-positive cells were significantly increased in the ASC-J9® (J9) + IR treated C4-2 (a) and CWR22Rv-1 (b) cells. (c) Fewer TUNEL-positive cells were shown in IR + J9 treated SV-HUC cells. (d-e) Western blot shows cleaved PARP-1 increases in C4-2 (d) and CWR22Rv-1 (e) cells. (f) The cleaved PARP-1 does not show expression in IR + J9 treated SV-HUC cells. (g-h) Transducing C4-2 (g) cells with scr or shAR, then applying IR, can enhance atypical PARP-1 cleavage and can suppress pATR (h). (i-j) Treating with ASC-J9® can suppress IR induced pATR-CHK1 activation in C4-2 (i) and CWR22Rv1 (j) cells. (k) Treating cells with ASC-J9® for 16 h, then irradiating cells, can result in G2-M phase arrest bypass (left) in C4-2 cells (quantitation at right). (l-m) ASC-J9® treatment could suppress IR-induced ATR phosphorylation, but not treatment with antiandrogen CAD or Enz in C4-2 (l) and CWR22Rv1 (m) cells compared to DMSO (DM) treatment group. (n-o) ASC-J9®, but not CAD or Enz treatment, could trigger IR-induced apoptosis in C4-2 (n) and CWR22Rv1 (m) cells. For A-C, data are presented as Mean ± SEM, *P < 0·05, **P < 0·01, ***P < 0·001, n.s = not significant.
cells. We then measured the ROS generation through detecting DCF-DA, an indicator for cellular ROS, since early studies indicated that the major source of RT-induced DNA damage is via ROS production [35]. Results in Fig. 5c–d revealed that treatment of C4-2 (Fig. 5c) and CWR22Rv-1 (d) cells with ASC-J9® for 6 h before IR dramatically increased ROS generation, compared to IR alone. Endogenous GSH, an important antioxidant that prevents oxidative damage was also obviously decreased in C4-2 and CWR22Rv-1 cells treated with ASC-J9® (Fig. 5e-f).

Interestingly, in C4-2 cells, when we replaced ASC-J9® with AR-shRNA to suppress AR protein in the comet assay, we failed to see the obvious DNA damage effect (Fig. 5g), suggesting ASC-J9®-enhanced DNA damage may function via an AR-independent signal. Furthermore, treating the C4-2 (Fig. 5h) and CWR22Rv-1 (Fig. 5i) cells with CAD and Enz also failed to boost the DNA damage (increased tail/body ratio) or alter the ROS generation (Fig. 5j-k).

Together, results from Fig. 5a–k showing that ASC-J9®, and not AR-shRNA, CAD, or Enz, could modulate the ROS to alter DNA damage, indicated that ASC-J9® may function via its unique polyphenols structure, and not an anti-AR mechanism, to modulate oxidative stress [36]. Further study of this ASC-J9® AR-independent mechanism to alter the DNA damage may help us to better understand these interesting findings.

3.6. Preclinical study using the in vivo mouse model to demonstrate that ASC-J9® can increase radiosensitivity to better suppress PCa progression

To demonstrate all above in vitro data showing ASC-J9® could increase radiosensitivity to better suppress PCa progression in the
in vivo mouse model, we xenografted $5 \times 10^5$ C4-2 cells into nude mice, and mice were castrated 2 weeks after tumors formed. On the 14th day after castration, mice were treated with i.p. injections of ASC-J9® for 6 h prior to IR. Quantification of fluorescence intensity of body/tail ratio at right. (c-d) ROS level as measured by DCF-DA fluorescence in C4-2 (c) and CWR22Rv1 (d) cells with/without ASC-J9® treatment and 10 Gy IR. (e-f) Endogenous GSH after ASC-J9® treatment in C4-2 (e) and CWR22Rv1 (f) cells. (g) AR-shRNA (shAR) + IR does not dramatically enhance DNA damage in C4-2 cells, quantitation at right. (h-i) ASC-J9® (5 μM) treatment with antiandrogens (10 μM CAD and 10 μM Enz), could enhance IR induced DNA damage in C4-2 (h) and CWR22Rv1 (i) cells, with quantitation at right. (j-k) ASC-J9® (5 μM), but not 10 μM CAD or Enz treatment, increases ROS level in C4-2 (j) and CWR22Rv1 (k) cells as measured by DCF-DA. (l) Schematic representation of the roles of ASC-J9® in IR. For ROS (c-d and j-k) and GSH (e-f) measurement, data plotted were mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 in comparison to respective DMSO group.

4. Discussion

One of the major limitations of RT in suppressing solid tumors, including PCa, is that the solid tumor cells are in a hypoxic environment [37] that reduces the efficacy for RT. Radiation’s ability to kill cancer cells rapidly decreases in areas of oxygen depletion, because production of free radicals is reduced. Cancer cells with lower ROS status might be 2–3 times more resistant to RT than those in the normal condition [38], thereby reducing survival rates in patients. Our results clearly revealed that in PCa cells, adding ASC-J9® before IR dramatically increased ROS and decreased GSH generation compared to IR alone (Fig. 5c–f).
Fig. 6. Tumor regrowth and apoptosis in xenograft nude mouse model. C4–2 cells were subcutaneously xenografted on the flanks of nude mice for 4 treatment groups, including non-IR, 8Gy IR, 75 mg/kg ASC-J9®, and 8Gy IR + J9. (a) Photograph for treatment of xenografted nude mouse model. (b) Representative images of each group at Day 0 and Day 24 (the middle circles contain group information and growth ratio of representative mice). (c) Tumor growth curve over time (n = 5), final tumor growth ratio was normalized with Day 0 value and compared by unpaired student t-test. (d) IHC staining of cleaved PARP-1 at 4 days after IR treatment in C4–2 cells, *P < 0.05, **P < 0.01, ***P < 0.001.
Hence altered ROS status is one of the key mechanisms by which ASC-J9\(^{5}\) enhances IR efficacy in our studies.

The use of neoadjuvant ADT together with RT has been used to increase overall survival and cure rates. In addition, ADT also reduced PCa tumor sizes to allow using lower doses of IR to suppress PCa [39]. Other reports indicated that ADT in combination with RT might also be able to delay the development of castration resistant PCa [39–41]. However, most, if not all, current ADT using antiandrogens may function via preventing or reducing androgens from binding to AR and have little capacity to suppress AR expression [42]. Importantly, accumulating evidence demonstrates that androgen effects are not equal to AR effects, because other factors, such as growth factors, kinases, cytokines or co- regulators, can also function in a similar manner as androgens to transactivate AR in the castration resistant condition [43–47]. In addition, AR variants (ARVs) have been identified to contribute to radioresistance [48]. Although the current ADT and antiandrogens have certain effects to enhance RT efficacy [49], these compounds failed to suppress ARVs mediated DDR. Therefore, targeting the remaining functional AR/ARVs after ADT may have better therapeutic efficacy in suppressing PCa progression during the castration resistant stage [50,51].

Our unexpected finding that RT could enhance AR expression raised very important clinical questions as to whether the RT-enhanced AR might interrupt/reduce the continuation of RT therapy efficacy and if the RT-enhanced AR might also be able to reduce the efficacy of subsequent ADT with various antiandrogens after the development of the RT resistance. Our results reveal that using RT plus anti-AR agents, such as ASC-J9\(^{5}\) or AR-shRNA (Fig. 2a–d), yield better efficacies to suppress PCa. Since ASC-J9\(^{5}\) is a much smaller molecular compound, as compared to AR-shRNAs or microRNAs, it can easily be used for in vivo delivery [52–55], and early in vivo mice studies using i.p injection or oral gavage with ASC-J9\(^{5}\) have demonstrated clearly the AR degradation with few adverse effects [42,56–61]. Importantly, results reported here further identified ASC-J9\(^{5}\) not only has an AR degradation effect, it also has an AR independent mechanism to increase IR efficacy with little adverse effects or indeed, a slightly protective effect on the neighboring normal bladder cells during IR.

As RT with a higher dose of \(\gamma\)-radiation may also result in damage to normal tissues, especially normal bladder tissue, several radiosensitizers including Bevacizumab [62], Isosafavones [63,64], Panobinostat [65] and Sunitinib [66], have been developed to enhance the RT efficacy without increasing the \(\gamma\)-radiation dosage. Mechanistic studies suggested that these radiosensitizers might be able to function through multiple signals to alter the RT efficacy. For example, soy isosafavones were found to be able to enhance the efficacy of RT via inhibiting cell survival pathways with extra anti-oxidant and anti-inflammatory activities [63,64]. Results from ASC-J9\(^{5}\) studies suggest that this drug might function through multiple mechanisms including alteration of the pATR/CHK1 pathway to accelerate the RT-induced apoptosis, suppressing DDR system and inducing the ROS production.

Among the above three major mechanisms we studied, we found replacing ASC-J9\(^{5}\) with AR-shRNA to knock down AR allowed us to obtain similar results in activating cell apoptosis effects (Fig. 3g) and suppressing the ATR/CHK1 pathway (Fig. 3h), but not the ratio of tail/body in the comet assay (Fig. 3g). One of the possible mechanisms that underlie these contrasting results could be that knocking-down of AR with AR-shRNA failed to alter the intracellular GSH level as compared to ASC-J9\(^{5}\) treatment, which might then fail to boost the ROS levels during combining IR with AR-shRNA treatment. These contrasting results suggest that ASC-J9\(^{5}\) may have additional non-AR-mediated functions, beyond degrading AR, to enhance IR efficacy.

Finally, to better explain why ASC-J9\(^{5}\) can increase IR efficacy to suppress PCa cells, and have few adverse effects on the normal bladder cells that neighbor the PCa cells, we hypothesize that there may be higher basal levels of ROS existing in PCa cells than in the neighboring normal bladder cells [67]. Combining ASC-J9\(^{5}\) plus IR may result in an overall increase in endogenous ROS in PCa cells, which may exceed their tolerance threshold and suppress PCa cell survival even in AR negative PC-3 cells (Supplementary Fig. S3). In contrast, the neighboring normal bladder cells with a much lower basal level of ROS [68] may have much higher tolerance for ASC-J9\(^{5}\)-induced ROS. We also found that normal bladder cells generated much less ROS during the combined therapy of ASC-J9\(^{5}\) treatment with IR (Supplementary Fig. S4).

In summary, this preclinical study demonstrated that in both in vitro cell lines and the in vivo mouse model, a regimen that combines IR with ASC-J9\(^{5}\) treatment not only provided better efficacy over the current conventional RT + ADT with antiandrogen treatment to reduce PCa tumor size, it also resulted in no adverse effects on normal bladder cells. The limitation of this study is that even if ASC-J9\(^{5}\), as a radiosensitizer, truly improves RT outcomes, the effect is likely limited to decreasing local recurrences. For patients who eventually have distant rather than local recurrence, we did not set up an ideal model to evaluate the risk. In addition, with the in vivo model (subcutaneous implantation) in our study, we still cannot precisely evaluate the impact on the bladder function. The image guiding RT for small animal plus orthotopic PCa model, and bladder functional tests can help us to better address this question in future studies.

These results suggest that combining ASC-J9\(^{5}\) treatment with IR has the potential to be a novel therapy to help clinicians to better suppress PCa progression in humans.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.12.050.

Funding sources

This work was supported by NIH grant CA156700 and George Whipple Professorship Endowment, and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-112-113002).

Declarations of conflicts of interest

ASC-J9\(^{5}\) was patented by the University of Rochester, University of North Carolina, and AndroScience, and then licensed to AndroScience. Both the University of Rochester and author C. Chang own royalties and equity in AndroScience. The remaining authors have nothing to disclose as individuals.

Contribution statement

FC (1st author) performed the experiments, designed studies, collected data, and wrote manuscript draft. YC (equal contribution author) designed the studies, and assisted with paper interpretation. YS provided technical support. DC helped with paper revision. YN and GL worked on data analysis. PK helped with data interpretation. SY designed the studies and CC helped design studies and finished final manuscript writing.

Acknowledgments

We thank Mrs. Karen Wolf for help with editing and revision.

References

[1] Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6): 1079–92.
[2] Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378(9809):2104–11.
[3] Dal Pra A, Curry F, Souhani S. Combining radiation therapy and androgens deprivation for localized prostate cancer—a critical review. Curr Oncol 2010;17(5):28.
[4] Suzuki M, Amano M, Choi J, Park HJ, Williams BW, Ono K, et al. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 2006;165(5):525–31.
Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, et al. Androgen receptor

Stracker TH, Usui T, Petrini JH. Taking the time to make important decisions: the

Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mam-

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen

Heffernan TP, Kawasumi M, Blasina A, Anderes K, Conney AH, Nghiem P. ATR-Chk1

Hsu J-W, Hsu I, Xu D, Miyamoto H, Liang L, Wu X-R, et al. Decreased tumorigenesis

Hara I, Miyake H, Yamada Y, Takechi Y, Haras Gotoh A, et al. Neoadjuvant androgen

Lai KP, Huang CK, Chang YJ, Yamashita S, Li Li, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 2013;182(2):460–73.

Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132–8 [discussion 8-9].

Sharifi N, Farrar WL. Fundamentals of steroid chemistry and biochemistry. Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian J Endocrinol Metabol 2011;15(4):261.

Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007;410:297–321.

Rockwell S, Dobrucki JT, Kim EY, Marrison ST, Vu YT. Hypoxia and radiation therapy: past, ongoing research, and future promise. Curr Mol Med 2009;9(9):442–58.

Harvey EM, Bae K, Hanks CE, Porter A, Grignon DJ, Brevent HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of effective androgen deprivation in locally advanced prostate cancer. J Clin Oncology 2008;26(15):2497–504.

Kulaseperumal PA, Mohan S, Gopalan M, Reddy EA, Reddy CA. Higher than standard radiation doses (≥ or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;64(3):567–74.

Hara I, Miyake H, Yamada Y, Takechi Y, Haras Gotoh A, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002;9(6):322–8 [discussion 8].

Lai KP, Huang CK, Chang YJ, Yamashita S, Li Li, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 2013;182(2):460–73.

Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132–8 [discussion 8-9].

Sharifi N, Farrar WL. Fundamentals of steroid chemistry and biochemistry. Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian J Endocrinol Metabol 2011;15(4):261.

Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007;410:297–321.

Rockwell S, Dobrucki JT, Kim EY, Marrison ST, Vu YT. Hypoxia and radiation therapy: past, ongoing research, and future promise. Curr Mol Med 2009;9(9):442–58.

Harvey EM, Bae K, Hanks CE, Porter A, Grignon DJ, Brevent HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of effective androgen deprivation in locally advanced prostate cancer. J Clin Oncology 2008;26(15):2497–504.

Kulaseperumal PA, Mohan S, Gopalan M, Reddy EA, Reddy CA. Higher than standard radiation doses (≥ or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;64(3):567–74.

Hara I, Miyake H, Yamada Y, Takechi Y, Haras Gotoh A, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002;9(6):322–8 [discussion 8].

Lai KP, Huang CK, Chang YJ, Yamashita S, Li Li, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 2013;182(2):460–73.

Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132–8 [discussion 8-9].

Sharifi N, Farrar WL. Fundamentals of steroid chemistry and biochemistry. Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian J Endocrinol Metabol 2011;15(4):261.

Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007;410:297–321.

Rockwell S, Dobrucki JT, Kim EY, Marrison ST, Vu YT. Hypoxia and radiation therapy: past, ongoing research, and future promise. Curr Mol Med 2009;9(9):442–58.

Harvey EM, Bae K, Hanks CE, Porter A, Grignon DJ, Brevent HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of effective androgen deprivation in locally advanced prostate cancer. J Clin Oncology 2008;26(15):2497–504.

Kulaseperumal PA, Mohan S, Gopalan M, Reddy EA, Reddy CA. Higher than standard radiation doses (≥ or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;64(3):567–74.

Hara I, Miyake H, Yamada Y, Takechi Y, Haras Gotoh A, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002;9(6):322–8 [discussion 8].

Lai KP, Huang CK, Chang YJ, Yamashita S, Li Li, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 2013;182(2):460–73.
Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, et al. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer 2010;62(7):996–1000.

Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008;8:132.

Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013;72(3):537–44.

corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, et al. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys 2013;86(3):540–5.

Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8(7):579–91.

Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16(11):1295–322.